Alector Inc., a decade-old biotech specializing in neurodegeneration, detailed its pipeline at the 12th Annual Cantor Fitzgerald Global Healthcare Conference in September 2026, with a focus on its AL137 anti-amyloid-beta antibody and siRNA programs targeting tau and alpha-synuclein. The company, valued at $231 million and trading at $2.07 (down 8.81% from the prior close), remains below its fair-value estimate, though financials beyond valuation metrics were not disclosed during the presentation. CEO Dr. Arnon Rosenthal emphasized the company’s strategy to retain its Alzheimer’s assets in-house while pursuing partnerships for Parkinson’s disease programs, which face greater clinical trial challenges due to the lack of established biomarkers and imaging tools.
The lead candidate, AL137, targets the pyroglutamate epitope of amyloid-beta—a marker present in plaques and fibrils—with preclinical data showing superior brain exposure at half the dose of intravenous trontinemab (Roche’s second-generation anti-amyloid antibody). Subcutaneous delivery achieved at least 150 mg/mL concentration, enabling a 2 mL injection. Compared to first-generation drugs like lecanemab and donanemab, which demonstrated 25–30% cognitive slowing over 18 months but faced ARIA safety concerns, AL137’s approach avoids the anemia and infusion reactions seen in second-generation therapies. Competitors like Denali Therapeutics and AbbVie’s Corsana have similarly reduced anemia by sacrificing effector function, a trade-off Alector argues undermines efficacy.
Phase I trials for AL137 are underway: a single-ascending-dose study in healthy volunteers in Australia is scheduled to begin in April, testing at least four dose cohorts in a threefold increment. The multiple-ascending-dose study in U.S. Alzheimer’s patients is expected in the third quarter, enrolling 60 participants across four cohorts. The trial will use PET imaging to track amyloid-beta plaque reduction, serum and CSF biomarkers (including p-tau217), and monitor for anemia, infusion reactions, and ARIA. Data will be reported on an ongoing basis.
Alector’s tau siRNA program, designed for subcutaneous delivery, showed a 70–80% reduction in tau mRNA across non-human primate brain tissues over three months, outperforming intrathecal antisense approaches (e.g., Biogen/Ionis) by achieving more uniform distribution without intrathecal side effects. The program is expected to enter the clinic next year. Meanwhile, its alpha-synuclein siRNA program demonstrated 94–95% mRNA knockdown in non-human primates, targeting Parkinson’s disease with a three- to six-month dosing regimen. The company seeks partnerships for these programs, given the complexity of Parkinson’s trials, while retaining its Alzheimer’s pipeline in-house.
The company’s GCase enzyme replacement therapy leverages its blood-brain barrier technology to stabilize the enzyme 50–100 times more, enabling peripheral delivery for Parkinson’s and Lewy body dementia. With Alzheimer’s affecting 65 million people and Parkinson’s impacting 10 million globally, Alector’s strategy balances internal development with strategic partnerships to accelerate its clinical and commercial progress.
Alector’s stock performance reflects broader biotech volatility, with a 52-week range of $1.09–$3.40. Analysts note its financial health as
